Federal Judge Halts National Institutes of Health's Grant Policy Overhaul Citing Legal Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 06 2025
0mins
Source: Benzinga
Federal Court Ruling: A federal court issued a nationwide preliminary injunction against the NIH's decision to reduce and cap indirect cost rates for biomedical research grants, preventing the implementation of a policy that could disrupt billions in funding and ongoing research.
Legal Challenges: The NIH's abrupt policy change faced backlash from 22 state attorneys general, medical associations, and universities, leading to lawsuits claiming violations of federal regulations and potential harm to critical clinical trials and medical advancements.
Analyst Views on FXH
Wall Street analysts forecast FXH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FXH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 118.125
Low
Averages
High
Current: 118.125
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
